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1. Introduction 
Giant cell (temporal) arteritis (GCA) is characterized by a granulomatous inflammatory 
reaction that penetrates all layers of the wall of medium- to large-sized arteries (1). The 
transmural vasculitis is particularly prone to involve cranial arteries such as the superficial 
temporal artery (TA), but not infrequently the disease extends to involve large muscular 
arteries including the subclavian and axillary arteries and the aorta.  
The earliest recorded description of GCA dates to the 10th century when Ali Ibn Isa of 
Baghdad in his memorandum book remarked on the relationship between inflamed arteries 
and visual symptoms (2). An even earlier case of GCA is disclosed in a photograph of 
carving of a blind harpist with swollen eyelids and prominent temporal arteries from a 
Egyptian tomb of Pa-Aton-Em-Heb dating back to 1350 BC  (3). Moreover, the painting by 
the Flemish painter Jan van Eyck (1436) “The holy Virgin with Canon van der Paele” may 
also represent an early case of GCA (4). The canon had prominent temporal arteries and 
diffuse swelling of the hand (5), the latter possibly indicating coexistent PMR. The tortous 
and inflamed artery seen in the portrait of Lorenzo Gambietti by Piero di Cosimo in 1502 is 
also suggestive of GCA (5). Thus, although GCA may have existed for several centuries 
there are rather few definite historical documentations of its existence. As GCA 
preferentially affects persons aged 50 years and more, one possible explanation is the low 
average life expectancy in ancient times, exposing few individuals to the risk of contracting 
GCA. 
The first clinical description of GCA was given by Jonathan Hutchinson in 1890 (St. 
Bartholomew`s Hospital, London) who was asked to examine Mr. Rumbold, an 80 year old 
father of a porter at the London Hospital who had “red streaks on his head” which were so 
painful that they prevented him from wearing a hat (6). Forty-two years later (1932), the first 
histopathological evidence of a granulomatous vasculitis in the temporal arteries was 
reported by Horton, Magath and Brown at a Mayo Clinic staff meeting in 1932 (7). In 1937, 
Horton and Magath added to their former report the prominence of headache, the difficulty 
chewing food, and transient diplopia (8). Blindness as a complication of GCA was, however, 
first recognized by Jennings in 1938 (9). In 1941, Gilmoure (10) suggested the presence of 
giant cells as characteristic for the disease which he called “giant cell chronic arteritis”. 
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During the 1930ies, the term “Temporal arteritis” was gradually introduced, whilst the 
designation “Cranial arteritis” was coined by Kilbourne and Wolff in 1946 (11) to point out 
that the temporal artery is not the only scalp artery affected in GCA. 
The most frequent complaints of GCA are head-ache and malaise. However, GCA may also 
present as a systemic inflammatory syndrome characterized by non-specific constitutional 
symptoms related to systemic inflammation in the absence of focal ischemic symptoms. This 
is often referred to as “silent or masked GCA” (12). On the other hand, the disease may also 
present with minimal or absent systemic manifestations, but with organ dysfunction such as 
visual loss or peripheral neuropathy. The term “Occult GCA”, coined by Simmons and 
Cogan in 1962 (13) is often used to denote such a disease variant (14). GCA rather frequently 
coexists with polymyalgia rheumatica (15), affects most often persons of Nordic origin (15) 
and almost exclusively involves individuals 50 years or older (15, 16).  
The annual incidence of GCA among persons 50 year or older has been estimated to 
29/100000 (15), but autopsy studies have indicated a substantially higher incidence (17). It is 
possible that physician awareness is responsible for the progressive increase in the incidence 
that has been observed over the past two to five decades in different parts of the world (18, 
19), conceivably remaining stable in the recent years (20). Mortality in GCA appears similar 
to that of the general population (21, 22). The cornerstone of treatment is represented by oral 
glucocorticosteroids (CS), but new therapeutic options which better control disease activity, 
exhibiting lower incidences of side effects and reducing disease complications are highly 
warranted. 
2. Age and sex 
In GCA, there is a typical female excess across all age groups (15, 16, 20, 23, 24, 25). 
Although GCA is almost invariably seen in individuals 50 years and older, arteritis of the 
temporal arteries is occasionally diagnosed in persons younger than 50 years (26). Temporal 
arteritis in the young may be separated into three groups. First, a localized eosinophilic 
arteritis confined to the temporal arteries (27), often without evidence of granulomatous 
inflammation (28). Systemic manifestations may be absent or minimal and the disease 
generally follows a benign clinical course without ischemic complications (28). Excision of 
the involved section of the temporal artery is often curative and CS are not required (28). 
Second, temporal arteritis may accompany other systemic connective diseases such as 
polyarteritis nodosa, Churg Strauss vasculitis, thrombangitis obliterans, or HIV infection 
(29). Third, a clinical and histological picture indistinguishable from that seen in adults may 
be observed. Although well documented, GCA among younger persons is exceptionally 
rare. 
3. Common clinical manifestations 
Head-ache At diagnosis, head-ache is reported by the vast majority of patients. In one study 
(25), it was present at onset in 54.1% and at diagnosis in 84.6%. The head-pain is classically 
located to the temporal regions, but occipital, frontal, or general headache is often 
encountered (25, 30, 31). In one case series, 17% of patients with biopsy-proven GCA had an 
initial presentation of occipital pain (31). Some patients report pain behind the ears which 
may be associated with vertigo and deafness (32).  
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4. Constitutional and musculoskeletal manifestations 
Constitutional symptoms very often accompany local ischemic manifestations. Asthenia, 
malaise, low-grade fever, night sweats, loss of appetite and weight loss are reported by 
more than one third of patients (2, 25, 33, 34). Fever is usually low-grade, but occasionally it 
is high and associated with night sweats (2). In some cases, fever is the presenting 
manifestation or the only feature of GCA (35). Patients may report joint pain, but contrary to 
Polymyalgia rheumatica, frank arthritis appears to be very rare (25, 34).  
5. Jaw claudication 
Jaw claudication manifests as jaw-pain which is noted particularly when the patient chews 
solid food or talks at length (2). It is seen in up to 50 % of patients with a full-blown clinical 
picture of GCA (2, 25, 30, 33), but may in many cases be absent at the very onset of disease 
(2, 25). Jaw claudication usually develops shortly after some minutes of chewing and is 
promptly relieved by resting the muscles of mastication (2, 33). It is due to masseter 
ischemia caused by vasculitis and occlusive stenosis of the maxillary artery, a branch of the 
external carotid artery. As jaw claudication is explicitly rare in other diseases, it is a high 
predictor of GCA, although not pathognomonic (30). 
6. Ophthalmologic manifestations 
The most feared complication of CGA is visual disturbances. The incidence of 
ophthalmologic manifestations varies from 14-70%, depending on the selection of patients 
and methods of ophthalmological examinations (25, 36, 37, 38, 39, 40). Consequently, 
incidences of visual impairment estimated in population surveys range from 1-21%, in 
hospital-based studies from 0-30% and from 48-65% among patients selected from 
departments of eye diseases (25). There is no unanimous consensus regarding suggestions of 
a progressive decline in the proportion of patients with visual manifestations during the last 
2 to 3 decades (39, 40, 41).  
The most common ophthalmologic manifestation is visual loss (97.7%) followed by diplopia 
(6-21%). The visual loss is most often unilateral (38), and it may be either transient or 
permanent (42). Other visual disturbances are bitemporal visual field defects due to 
vasculitic damage to the arteries that supply that optic chiasm (42), homonymous visual 
field defects due to vascular involvement of the retrochiasmal visual sensory pathway (42), 
papillary disturbances and acute ocular hypotony (42). Visual hallucinations may occur, and 
in most cases these occur after the patient is bilaterally blind (42). Several cases of Charles 
Bonnet syndrome have been reported (43, 44). 
Visual manifestations usually present early in the disease course, and are rarely seen after 2-
3 years of disease (25, 45, 46, 47). In one study (25) visual impairment occurred at onset in 
only 2.7% as opposed to 17.9% at the time of diagnosis. Loss of vision after the first two 
weeks of CS therapy seems to be exceptionally rare (48). In one study (36), the probability of 
additional visual loss due to GCA was 13 % at 5 years in patients who presented with visual 
loss. The probability of visual loss due to GCA was 1 % at 5 years in patients with intact 
vision when oral CC treatment was started (36). If bilateral visual loss develops, the interval 
between the first and second eye is usually only a few days (49, 50).     
Visual loss is related to anterior ischemic optic neuropathy (AION)(51), which is  most 
commonly caused by narrowing or occlusion of the posterior ciliary arteries (32). These 
arteries provide blood flow to the optic disc and the choroid (42).  Consequently, the early 
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fundoscopic appearance noted in AION consists of slight pallor and oedema of the optic 
disc with scattered cotton-wool patches and small hemorrhages. Later optic atrophy occurs. 
Such patients often report a feeling of a shade covering one eye (42). It occurs abruptly or it 
may be preceded by episodes of transient monocular loss of vision (42). Of all patients with 
AION, only 5 % have concomitant GCA (42).   
Central retinal artery occlusion is the second most common cause of visual loss, affecting 10-
13% of patients with visual disturbances (42, 38, 51). However, it should be noted that only 
5-10 % of patients with central retinal artery occlusion have GCA (42). Usually, it develops 
rather abruptly and permanently (42). Posterior ischemic optic neuropathy is much less 
common (42). A rather rare cause of visual loss in GCA is occipital lobe infarction (52, 53). 
Importantly, of patients with visual manifestations, transient visual loss is reported by  
5-54 % (47, 54, 55, 56). Transient monoocular blindness (ameurosis fugax) results from 
insufficient perfusion of the optic nerve, retina or choroid and precedes the development of 
permanent visual loss by an average of 8.5 days (33, 40, 42, 57). Ameurosis fugax should 
thus be regarded an ominous sign of impending blindness. In rare cases, transient visual 
disturbances preceding permanent visual loss may alternate between the two eyes (42). 
The risk of developing visual disturbances has been associated with low disease activity (37, 
58, 59), high disease activity (37, 45, 60), anemia (61), older age (37, 38), disc swelling (37), 
and a history of hypertension (62). In some studies, the best predictors for the development 
of severe cranial ischemic events included the absence of high CRP and ESR levels at 
diagnosis, absence of systemic manifestations such as fever and weight loss, and a past 
history of ischemic heart disease (58, 62). On the other hand, one study (60) showed an 
increased frequency of visual ischemic events in patients with ESR values ranging between 
70 and 100 mm/h at the time of disease diagnosis. Similarly, another survey (63), found no 
increased risk of visual loss or other cranial ischemic events in patients with low ESR (< 40 
mm/h).  Histologically, the presence of giant cell cells has been associated with increased 
risk of visual loss (64), but this finding needs to be confirmed. A recent retrospective study 
showed a frequency of permanent visual loss as high as 70% among patients lacking 
headache at diagnosis (65). Clearly, further research is needed to define predictors of visual 
manifestations that can be favorably used in everyday clinical practice.7.  
Large vessel vasculitis Involvement of large vessels may be seen in 14-25% of cases with 
GCA (66, 67, 68, 69). Both aortic aneurysm formation and peripheral large vessel vasculitis 
of the extremities may be observed (66, 70, 71, 72, 73, 74). In rare cases, arteritis involving the 
mesenteric vessels may develop both as an initial manifestation of GCA and antedating its 
diagnosis (75). About 1/3 of such patients die.   
In large-vessel arteritis involving the upper extremity, the subclavian and axillary arteries 
are most often affected (76). In about 1/5 of cases with large vessel vasculitis of the upper 
extremities, the brachial arteries are involved (68). The clinical picture is characterized by 
claudication of the arms, bruits over the carotid, subclavian, axillary and brachial arteries 
and absent or decreased pulses in the neck or arms. Paleness of hands upon use of upper 
extremity may also be observed (77). Unilateral manifestations are more frequent than 
bilateral manifestations (68).  
In rare instances, lower extremity vasculitis develops in which involvement of the 
superficial femoral arteries is most frequently seen (68, 71). Other lower extremity vasculitis 
includes the internal iliac artery, the common femoral artery, the deep femoral artery  and 
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the popliteal and anterior tibial arteries (68). Occasionally, GCA may present as a rapidly 
progressing lower extremity claudication with elevated inflammatory markers whereas 
cranial symptoms may be absent (71, 78).  
In general, TAB may be normal in 50 % of patients with large vessel vasculitis (76). Thus, in 
many cases the differentiation between GCA and Takayasu arteritis may be difficult, 
although the latter often occurs at a younger age than the former. Both upper and lower 
extremity vasculitis in GCA may precede other manifestations of the disease (71), or it may 
be identified in association with GCA diagnosis and even develop after the onset of GCA 
(68). According to one study, the outcome of upper and lower extremity vasculitis in GCA 
seems rather good (68). Approximately 3 years after diagnosis, 80-90% of cases will either 
experience disappearance or improvement of clinical manifestations (68). Slightly more than 
10% will have a deterioration of clinical manifestations (68). However, in another study (71) 
adressing lower extremity vasculitis exclusively, significant morbidity was observed as 
several patients were subjected to revascularization surgery and limb amputation. It is thus 
possible that the outcome differs between patients presenting with rapidly progressing 
lower limb claudication and those with less predominant clinical manifestations of lower 
limb vasculitis.  
GCA involving the aorta was first described by Sproul and Hawthorne in 1937 (80) and is 
increasingly recognized conceivably due to improved imaging techniques. Case-series 
employing PET for diagnosis have found evidence of aortitis in over half the cases (81). Of 
such cases, both the thoracic and abdominal aorta may be affected (73). A study from the 
Mayo clinic in 1995 showed that 14 of 96 (15%) patients with GCA had an aortic aneurysm 
(9 thoracic and 5 abdominal)(69). Thus, patients with GCA were found to be 17.3 times more 
likely to have a thoracic aortic aneurysm and 2.4 times more likely to develop abdominal 
aortic aneurysm than age-related controls. Some have suggested it to be more common in 
men than females (74). Aortic dissection may be the first manifestation of GCA (82), but in 
the majority of cases, development of aortic disease occurs after the diagnosis of GCA (71). 
In many cases, aortic aneurysms occur late, years after the onset of the disease and even 
years after the completion of CS therapy, so that patients will often have left their 
rheumatologist (69, 76, 83). Moreover, most cases are asymptomatic unless dissection and 
rupture develop (66, 69, 72, 84). As no absolute correlation between high disease activity and 
evolvement of aortic disease seem to exist, diagnosis of aortic GCA disease is highly 
dependent on screening procedures for such events.  
Involvement of the aorta may be diagnoses by ultrasonography, CT or MRI (72, 73, 85). 
Vasculitis of the aorta and peripheral vessels may also be visualized by increased vascular 
uptake on 18FDG-PET (86, 87, 88, 89), but it is not clear if this is specific to vasculitis or 
simply a marker of any type of wall injury and tissue repair (76). Its specificity and 
sensitivity for diagnosing large vessel vasculitis have therefore been questioned (90). 
Although the recent advent of combined functional and anatomic imaging with PET-CT 
scanners allows anatomic correlation and exact localization of pathological lesions, PET 
scanning is associated with high costs and not available in all hospitals. Thus, at present it 
should not be recommended as a routine screening procedure in GCA. As most aneurysms 
develop in the ascending aorta, a yearly transthoracic echo and two-view chest radiograph 
could be considered as a reasonable screening approach (76). A yearly ultrasound screening 
in GCA for abdominal aneurysms is also likely to be cost effective (76).  
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In one report (69), 44% of patients with thoracic aortic aneurysm, died suddenly of 
dissection and 33% developed aortic regurgitation. However, subsequent investigations 
have concluded with a rather favorable outcome of aortic disease in GCA except for those 
patients that proceed to develop dissection or rupture (89, 91). In one study, follow-up at 6 
months showed complete disappearance in 8.8%, improvement in 47.1%, unchanged in 
41.2% and deterioration in 2.9% (72). A French study using CT scans to diagnose aortitis, 
also disclosed a more favorable prognosis as 10 of 11 patients achieved complete resolution 
or improvement at follow-up (92).  
Risk factors for development of large vessel vasculitis in GCA have been insufficiently 
investigated. It has, however, been suggested that an aortic insufficiency murmur at the 
time of GCA diagnosis, hyperlipidemia, coronary artery disease at any time and high ESR in 
combination with polymyalgic symptoms, and hypertension are factors associated with 
aortic aneurysm or dissection (76, 83, 93). It should be noted, however, that less than 10 % of 
patients with noninfectious aortitis have GCA (94). 
8. Neurologic manifestations 
GCA presenting with neurological manifestations is exceptionally rare, occurring in only 
four of 260 cases (1.5 %) in one report (34). Neurological manifestations of GCA most 
probably result from arteritis of the vasa vasorum of peripheral nerves and consist of 
neuropathies, including mononeuropathies and peripheral polyneuropathies of the upper 
and lower extremities (95). On the other hand, vasculitis of the central nervous system is 
extremely rare and inflammatory lesions are very rarely found beyond 5 mm after the 
artery`s penetration of the dura. Bley et al. (96) studied the thin walled intradural arteries of 
the circle of Willisi by MRI and did not find any signs on MRI suggestive of mural 
inflammation. Some rare neurological manifestations are summarized in Table 1. 
According to most reports, cerebrovascular ischemic events are found in 3-15% (65, 97, 98) 
of GCA, but are due to involvement of the extradural segment of the vertebral and carotid 
arteries. In one study, eight of 287 patients (2.8%) had strokes between the onset of GCA and 
4 weeks after the onset of CS (97). Lesions due to involvement of the vertebrobasilar 
territory were seen more often than those caused by involvement of the carotids (97, 99). 
Patients with strokes had more commonly permanent visual loss and were more frequently 
smokers (97). In another study (99), the same incidence (2.8%) of strokes was observed, but 
the internal carotid arteries were involved in 4 patients and the vertebrobasilar arteries in 3. 
Interestingly, CT and MRI revealed small cerebral and cerebellar infarction, but at necropsy 
generalized GCA involving medium and cerebral vessels was found in one case (99). 
Multiple ischemic strokes despite escalating immmunosuppressive therapy may also 
develop (100, 101), in which both anterior and posterior circulations are involved bilaterally 
in a characteristic location where the arteries penetrate the dura (100). Thus, strokes occur in 
a few patients with GCA and are in the overwhelming majority of cases due to 
thromboembolic disease localized to the carotid and vertebrobasilar supplied areas of the 
brain. However, strokes due to atherosclerosis and iatrogenic effects of CS should not be 
overlooked (101). Finally, in some cases the cause of progressive stroke may be due to CC 
rather than the disease itself (102), suggesting that replacing GC with anticoagulants should 
be considered.  
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9. Scalp necrosis 
Scalp necrosis in GCA was first described by Cooke and coworkers in 1946 (103), and 
remains an explicitly rare disease manifestation of GCA. It is most often localized to the 
frontal and parietal parts and is often bilateral (Picture 1). As the scalp has an excellent 
blood supply, development of scalp necrosis signalizes severe vasculitis, involving most 
superficial arteries of the scalp. Consequently, it is often associated with severe GCA 
frequently including both cerebral and coronary artery occlusions (41%) and irreversible 
visual loss (67%)(104). Somewhat surprising, scalp necrosis usually heals completely after a 
few weeks (105), although sequela in the form of scarring may be seen (106). According to a 
review of 78 cases reported in the literature, scalp necrosis never developed after onset of 
therapy with corticosteroids (107). However, a case was recently reported in whom scalp 
necrosis antedated the initiation of therapeutic corticosteroids (108).    
10. Tongue necrosis 
The tongue has an excellent blood supply and is usually minimally affected in GCA (109). 
However, in rare cases, necrosis and gangrene of the anterior portion of the tongue may 
develop (110). Bilateral lingual necrosis has also been reported (109). It has been suggested 
that tongue necrosis most often develop during initial tapering of corticosteroid dosage 
(111). Tongue necrosis is caused by lingual arteritis (109). Occasionally, patients suffering 
from GCA report loss of taste (112) which may be related to facial artery giant cell arteritis. 
 
Neurological 
- Dementia (111) 
- Psychosis (33) 
- Coma (114) 
- Seizures (115) 
- Spinal cord infarction (116, 117) 
- Subarachnoidal hemorrhage (33) 
- Neuropathies (95) 
- Mononeuritis multiplex (118) 
- Trigeminal neuralgia (119) 
- Bilateral peroneal nerve palsy (120) 
- Cerebral vein thrombosis (121) 
- Occipital infarction (118, 122) 
- Transient ischemic attacks (123, 124) 
Oral manifestations (125) 
- Trismus (125) 
- Throat pain (126) 
- Hoarsness (126) 
- Dysarthria (125, 127, 128) 
- Chin numbness (125) 
- Glossitis (129, 130) 
- Macroglossia (125, 131) 
- Lip or tongue necrosis (125) 
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- Odontogenic pain (33) 
- Dysphagia (125) 
- A submandibular mass (125) 
- Head, neck and facial swelling (132, 133)  
Audiovestibular manifestations (134) 
- Hearing loss (33, 134) 
- Tinnitus (134) 
- Vertigo(134) 
- Dizziness (134) 
- Spontaneous nystagmus (134) 
- Earache? (125) 
Orbital manifestations 
- Ptosis (135) 
- Eye pain (125) 
- Chemosis (134) 
- Ophthalmoplegia (135, 136) 
- - Complete abducens nerve palsy (136, 137)- Third nerve palsy (135, 136) 
- Lid edema (135) 
- Episcleritis (135) 
- Proptosis (135, 137) 
Other manifestations 
- Bowel infarction (138, 139, 140, 141) 
- Arteritis of the myometrium,ovaries, paraovarian tissue and fallopian tubes  (142, 143, 
144) 
- Pericardial and pleural effusions (145, 146, 147, 148, 149) 
- Pleural thickening, nodules of variable size and reticular lesions (149) 
- Cough, sore throat and hoarseness (149) 
- Myocardial infarction (150, 151, 152, 153, 154)  
- Breast involvement (155, 156) 
- Syndrome of inappropriate antidiuretic secretion (157) 
- Raynaud`s phenomenon (158) 
- Microangiopathic hemolytic anemia (159) 
- Carotidynia (160, Cid AR 1998 ref 79) 
- Membraneous glomerulopathy and nephrotic syndrome (161) 
Table 1. Less commonly reported clinical manifestations in GCA 
11. Concomitant polymyalgia rheumatica 
Polymyalgia rheumatica (PMR) and GCA frequently coexist (25, 162, 163), an association 
noted by Porsman as early as in 1951 (164). PMR may precede GCA or develop after GCA 
diagnosis. Whether or not PMR and GCA represent two separate disease entities which 
frequently overlap or are one common disease with different clinical expressions remains a 
controversial issue. The frequent concomitant occurrence of PMR and GCA suggests a 
common disease denominator whereas the discrepant clinical picture of TA and PMR may 
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indicate two separate disease entities. The occurrence of articular and periarticular 
inflammation seen almost exclusively in PMR suggests separate disease entities (165). On 
the other hand, positron emission tomography (PET) scan findings of increased uptake of 
fluorodeoxyglucose in the thoracic vessels in many patients with PMR suggest a common 
vasculitic disorder (166, 167). Finally, the reported incidence of biopsy-proven TA among 
patients with pure PMR varies considerably, from 4 to 70% which makes it difficult to reach 
an overall conclusion regarding the relationship between TA and PMR (25, 168, 169, 170).  
Patients presenting with both PMR and GCA often run a severe disease course, and 
maintenance doses of oral CS are on average often higher compared to patients presenting 
pure PMR or isolated GCA (171, 172).  
12. Clinical examinations 
In patients suspected of suffering from GCA rather few clinical examinations are 
mandatory. As GCA affects individuals older than 50 years who rather frequently suffer 
from other diseases, a general medical examination is compulsory. Examination of aorta and 
large arteries of the upper and lower extremities to reveal bruits and diminished pulses is 
strongly recommended. 
Physical examination of the frontal and parietal branches of the temporal arteries may reveal 
tenderness on palpation, absent or reduced pulsation and thickening of the vessel. General 
scalp tenderness is rather frequently present and may be worsened by brushing or combing 
the hair. 
A thorough examination for ophthalmological symptoms is strongly recommended. 
Symptoms indicating coexistent PMR should not be missed. Patients with uncomplicated 
GCA should be informed about the risk of ischemic complications and asked to report back 
immediately if such events develop. 
13. Laboratory investigations  
Acute phase reactants are increased in the overwhelming majority of GCA (25). An ESR of 
40 mm/hour or more has been noted in more than 90 % of patients (61, 63). Less than 1-2% 
have normal levels of both ESR and CRP (25, 173, 174). GCA with normal ESR has, however, 
been reported (175, 176, 177), even in patients with visual disturbances (176, 178) and 
devastating central nervous system complications (179). Interestingly, when patients with 
GCA and normal ESR were followed-up, these patients were never able to mount a high 
ESR during subsequent episodes of inflammation caused by infection which may imply a 
genetically determined blunted cytokine response to inflammation (63). ESR and CRP are 
relatively lower in patients with occult GCA according to some observations (14). These 
patients often have a longer diagnostic delay (180).  Both leucocytosis (61), thrombocytosis 
(61, 181, 182), and normocytic normochromic anemia (61) may be encountered. Liver 
function tests are frequently abnormal, particularly elevations of serum alkaline 
phosphatase (62, 183). 
Recent research has explored the potential utility of other biomarkers for disease activity in 
GCA. A promising cytokine for monitoring disease activity in GCA is IL-6 as it is found in 
inflamed arterial walls and shows highly elevated serum levels in active GCA (184, 185). In 
one study, 89% of flares were associated with an elevated level of IL-6 while ESR elevations 
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accompanied 58% of flares (186). However, analyses of IL-6 are not readily available at most 
centers, and thus not suitable for routine measurements. Finally, more research is needed to 
explore whether or not serial assessments of circulating TNFǂ can aid in the monitoring of 
possible relapses in GCA (187). 
14. Imaging 
14.1 Ultrasound 
Color duplex ultrasonography of the temporal artery has been introduced as a means of 
improving the diagnosis of GCA. Besides revealing stenosis and vessel occlusions, 
ultrasound may also detect wall inflammation. 
Schmidt and coworkers described in 1997 the presence of a hypoechoic thickening around 
the lumen of the temporal artery, termed a “halo-sign” which represents edema of the vessel 
wall (188). The “halo-sign” may also be seen in subclavian, external carotid, occipital, 
axillary, facial, brachial, ulnar, common carotid, vertebral, radial and popliteal arteries (189). 
The frequent involvement of the occipital arteries in GCA may also be detected by 
ultrasonography (190). Thus, an ultrasonographic finding of a hypoechoic halo around the 
lumen of the temporal arteries has been advocated as a method of making the diagnosis of 
GCA rendering temporal artery biopsy (TAB) superflous. However, several studies have 
questioned the sensitivty of the “halo-sign” for the diagnosis of GCA. According to various 
reports, its sensitivity varies from 10-100% (191, 192, 193). In a meta-analysis of 23 studies, 
the “halo-sign” had a pooled sensitivity of 69% and a specificity of 82% compared with TAB 
(194). However, a bilateral “halo-sign” appears almost pathognomonic of GCA (193). In 
another report, Arida and coworkers (195) conducted an extensive metaanalysis of 
ultrasonograophy which disclosed a sensitivity of 68% and a specificity of 91% for the 
unilateral “halo- sign”, as well as 43% and 100%, respectively for the bilateral “halo-sign” 
for GCA diagnosis. 
The reasons for apparent discrepancies regarding sensitivity of ultrasound to detect the halo 
to diagnose GCA may have several explanations. First, sensitivity and specificity are highly 
dependent on the examiner as the method requires experience and expertice. Second, the 
quality of the sonographs employed in the different studies may vary. Third, the appearance 
of vessel wall abnormalities may also vary with the duration of the disease.  
A negative ultrasonographic finding at the onset of disease may be due to absence of early 
adventitial inflammation which is necessary to produce the oedema that causes the halo 
effect. It should also be noted that the halo disappears after commencement of steroid 
therapy, usually within 2-4 weeks (188, 189, 193). Finally, in some cases it is difficult to 
differentiate between inflammatory and noninflammatory temporal artery disease by 
ultrasonography (196). 
At present, ultrasonography should not replace temporal artery biopsy (TAB), but it can 
serve as a means for identifying sites suitable for surgical biopsies (197). Moreover, 
ultrasonography appears a promising method for diagnosing GCA in patients who decline 
surgical biopsies. In such cases, cautious interpretation of the test results based on clinical 
presentation and pretest probability of the disease is imperative (194). Clinicians responsible 
for the care of patients with GCA should be encouraged to use ultrasonography to detect 
large vessel vasculitis in GCA.  
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15. Magnetic resonance imaging 
MRI can detect inflammatory vessel wall changes (198) with a sensitivity of 80.6% and a 
specificity of 97% compared against a diagnosis of GCA based on the ACR criteria (199). 
According to other findings, the specificity and positive likelihood ratio of high resolution 
MRI are sufficiently high that a positive MRI combined with other clinical and laboratory 
data consistent with GCA may be useful in diagnosing GCA (200). It should be noted, 
however, that given the relatively low sensitivity of the test, a negative MRI would not be 
sufficient to rule out the diagnosis of GCA (201). 
Moreover, no definite concordance between MRI and acute phase assessed by CRP has been 
established (86).  Finally, to few studies have specifically addressed the suitability of MRI 
diagnosing arteritis in the temporal arteries (202). Although disputed (201) , MRI appears as 
a  favorable means to detect large vessel vasculitis, in any case when abnormalities such as 
vessel narrowing or obliteration have developed. 
16.
 18
Fluorodeoxyglucose-positrone emission tomography – 18FDG- pet-
scanning) 
  Similar to MRI, 18FDG-PET may be useful to detect large vessel arteritis but is associated 
with restricted availability and high costs. However, PET scanning may in the absence of 
reliable biomarkers for disease activity, represent the only method of disclosing active vessel 
wall inflammation. Preliminary results indicate that 18F-FDG PET could be a method 
exhibiting high sensitivity and specificity for GCA-related large-vessel inflammation (203, 
204, 205, 206).  
Others have found PET as a useful diagnostic tool in early stages of large vessel vasculitis 
and a powerful instrument to follow the treatment responses (88).  However, increased 
vascular up-take on PET should be interpreted cautiously as it is still unsettled whether or 
not such uptake represents inflammation requiring anti-inflammatory therapy or indicates 
inflammation associated with a healing process. One study found only a low, but non-
significant correlation of PET with CRP (201). At present, more investigation is needed 
before PET scan eventually can be included in the routine work-up and monitoring of GCA. 
The availability of the modality is, however, restricted, and the costs are of great concern. 
17. Temporal artery biopsy 
According to the British Society for rheumatology guidelines, TAB should be considered 
whenever a diagnosis of GCA is suspected (207). The EULAR recommendations, however, 
advocate that a TAB should be performed when GCA is suspected (208). Although a 
diagnosis of GCA according to the ACR criteria (199) can be made without histological 
confirmation, these criteria were constructed for use in research. For clinical work, the 
benefit of a pathological confirmation of the diagnosis should not be underestimated. Both 
at the start of disease and during disease course, a histological proof of GCA appears 
reassuring for both patients and clinicians. When patients develop serious adverse-effects 
due to long-term CS treatment, histopathological proof of the diagnosis helps to buttress the 
case for continued therapy (209). Moreover, GC therapy may cause serious side effects 
which may result in a medicolegal case. Morphological evidence of the disease will then 
provide proof that both diagnosis and treatment were appropriate. Finally, although scalp 
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necrosis, brow droop, chronic skin ulceration and stroke have been described, TAB is 
associated with low-morbidity (210). As emphazised earlier, an ultrasound should be 
performed to identify the most suitable location fo biopsy. 
Typical histopathological findings in GCA include infiltration of T lymphocytes, dendritic 
celles and macrophages in all layers of the arterial wall. Moreover, disruption of the internal 
elastic lamina, chronic granulomatous inflammation, multinucleated giant cells accumulated 
along the fragmented internal elastic lamina, thickening of the intima and luminal occlusion 
are frequently observed. In some cases, involvement is in seen exclusively in the small 
vessels external to the temporal artery adventitia (211).  PMR very often accompany GCA in 
such cases (211). 
The minimum length of the biopsy required for a definite diagnosis of GCA has been 
discussed in several reports. The basis for the discussion is the uneven distribution of 
arteritic lesions (212). Skip lesions have been described in 8.5-28.3% of positive biopsies (213, 
214, 215). Although lengths of biopsies shorter than 10mm are suggested to be sufficient for 
a diagnosis of GCA (216, 217), most authors recommend a minimum length of at least 1.5-2 
cm (218, 219, 220). Such a length would allow for tissue shrinking during fixation which is 
estimated to approximately 10 %.  
If the biopsy yields normal findings, a contralateral biopsy may be considered. However, the 
diagnostic yield of a second biopsy if the first one is negative is rather small. The percentage 
of patients with a negative biopsy on one side and a positive biopsy on the other  has been 
reported from 3 to 12.7 % (221, 222, 223). Given the low increase in sensitivity obtained by 
performing bilateral biopsies, careful diagnostic considerations should be undertaken before 
requesting a second biopsy. Moreover, a unilateral biopsy preserves an artery in the event 
that a diagnosis of GCA is considered in the future, and minimizes costs and physician time 
(224). In any way, commencement of therapy should not be delayed if clinical suspicion of 
GCA is high in spite of a first negative biopsy.  
The administration of immunosuppressive therapy such as CS may have little impact on the 
possibilities of detecting histological vasculitis during the initial phases of therapy. 
Specimens might show arteritis after 2-4 weeks of CS therapy (225, 226, 227, 228), although 
the frequency of positive biopsies is slightly reduced for each week of treatment (227, 229). 
Active vasculitis observed in TAB has been demonstrated after as long as 9 years after 
initiation of CS (230). Thus, TAB should be performed in all patients suspected of having 
GCA, but negative results on biopsy in patients treated for weeks should be interpreted 
with caution.  
In long-term CS treated patients, a histopathological picture of socalled healed-arteritic 
pattern has been observed. The three most reliable histopathological parameters of CS 
treated GCA were a complete or incomplete mantle of lymphocytes and epitheloid 
histiocytes located between the outer muscular layer and the adventitia, large 
circumferential defects in the elastic lamina and absent or few multinucleated giant cells 
(231). Patients exhibiting such histopathological features seemed to be at no risk of 
reactivation, early death, permanent blindness and cerebrovascular accidents (232).   
Of major concern is the low number of positive biopsies analyzed by pathological 
departments. Studies during the years 1976 to 2007 have reported findings of GCA in 13 – 
43.7 % of TABs (19, 226, 233, 234, 235). Consequently, predictive markers for a positive 
biopsy have long been searched for. In one study of TAB performed among patients 
suspected of having GCA, excluding patients with no evidence of temporal artery 
abnormalities, scalp tenderness, or jaw claudication, only 48% of the 125 biopsies would 
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have been performed (236). Fiftynine negative biopsies would have been prevented, but six 
positive biopsies would have been missed (236). The findings jaw claudication, weight loss, 
pathological temporal artery enlargement, recent head-ache, and scalp tenderness have all 
been found to predict a positive biopsy (226, 233, 236, 237). It is tentative to suggest that 
patients exhibiting none of these clinical features combined with a negative ultrasound 
should not be subjected to TAB  before all other causes of current inflammatory 
manifestations are ruled out. Finally, the frequencies of positive TAB reported in PMR have 
varied from 4-40% (25, 238), the results depending on the definition of “pure” PMR. At 
present, it is generally agreed upon that TAB is not indicated in patients with PMR in the 
absence of cranial manifestations (pure PMR), unless a high inflammatory response is 
present.  
18. Diagnostic and classification criteria 
18.1 Clinical suspicion 
A diagnosis of GCA should be considered in all patients 50 years or older with unexplained 
head-ache, a significant inflammatory response that is not explained by infection, other 
autoimmune diseases or malignancy, visual disturbances or signs of peripheral 
vasculopathy. The British society for rheumatology (207) recommends that clinical suspicion 
of GCA should be raised in a patient older than 50 years presenting with either abrupt-onset 
headache, scalp tenderness, jaw and tongue claudication, visual symptoms,  constitutional 
symptoms, polymyalgic symptoms or limb claudication. 
19. Diagnosis 
For scientific purpose, the ACR criteria are widely used (199). These criteria attempt to 
differentiate GCA from other vasculitides and include five items (Table 2). Presence of 
three or more of these five criteria is associated with a sensitivity of 93.5% and a 
specificity of 91.2%. It is noteworthy that according to these criteria, a diagnosis of CGA 
can be made in the absence of histopathological evidence. In a number of studies, patients 
with biopsy-proven GCA have been studied exclusively, hence hampering comparison 
with investigations based on the ACR criteria which include both biopsy positive and 
negative patients. Consequently, results should be presented separately for biopsy 
positive and negative cases allowing valuable comparison. It should also be noted that 
occult GCA and patients presenting large vessel vasculitis exclusively may not have been 
accurately represented in the ACR criteria. Furthermore, as the ACR criteria are not useful 
for making the diagnosis in individual patients (239), other diagnostic guidelines should 
be followed.    
 
1. Age 50 years or older 
2. New onset of localized headache 
3. Temporal artery tenderness or decreased temporal artery pulse, 
4. Elevated ESR 50 mm/hour or higher  
5. Biopsy sample including an artery, showing necroitizing arteritis, characterized by a 
predominantly of mononuclear cell infiltrates or a granulomatous process with 
multinucleated giant cells.  
Table 2. The ACR 1990 criteria for giant cell arteritis (199) 
www.intechopen.com
 
Advances in the Diagnosis and Treatment of Vasculitis 
 
266 
A diagnosis of Cranial arteritis requires the histological demonstration of localized vasculitis 
combined with associated clinical manifestations such as either head-ache and/or jaw 
claudication, visual loss and constitutional symptoms. Thus, a definite diagnosis of GCA 
classified as Cranial arteritis rests on the demonstration of inflammatory changes found on 
biopsy of the temporal arteries.  In cases of normal histopathological findings at vessel 
biopsy, a diagnosis of cranial arteritis should only be made after a thorough exclusion of 
other causes for the aforementioned clinical manifestations. In such cases, evidence of an 
elevated acute phase response should be regarded compulsory and detection of a halo by 
ultrasonography would strongly support the diagnosis of GCA.  
In patients with non-specific constitutional symptoms related to systemic inflammation in 
the absence of focal ischemic symptoms, but with histopathological proof of GCA, the term 
“Silent or masked GCA” or “systemic inflammatory syndrome” should be preferred.  As 
emphasized by Rahman & Rahman (32), the ACR criteria are likely to result in some false-
negative diagnoses of GCA, putting vision at risk. In silent or occult GCA, the risk of 
ischemic complications resulting in loss of vision is highly significant, requiring a high index 
of suspicion in order to diagnose GCA in patients with an atypical presentation. 
Some patients may show evidence of large vessel vasculitis in the absence of 
histopathological evidence of GCA, and without significant inflammatory symptoms. Such 
cases may be indistinguishable from Takayasu arteritis, and should thus be labelled Large 
vessel vasculitis, or if histopathological proof of granulomatous vasculitis is observed, the 
term Large vessel giant cell arteritis may be preferred. 
20. Differential diagnoses, malignancy and cardiovascular disease 
A TAB remains the gold standard test in the diagnosis of GCA, and few diseases can be 
mistaken for what turns out to be biopsy-proven GCA. Vasculitis of the temporal arteries 
has been reported in polyarteritis nodosa, Churg Strauss vasculitis, microscopic polyangiitis, 
Wegener`s granulomatosis, hepatitis B virus-related polyarteritis nodosa, hepatitis C virus-
related cryoglobulinemic vasculitis and rheumatoid vasculitis (29, 240, 241, 242), but the 
clinical features of these diseases distinguish them from TA. Primary systemic amyloidosis 
may present with a clinical picture of either PMR or GCA or both (243). 
Malignancy and Cardiovascular disease in Giant cell arteritis. Although suggested by some 
(244, 245), the majority of studies have been unable to find an increased risk of malignancy 
in GCA ( 246, 247, 248, 249, 250, 251). However, as GCA affects persons 50 years and older, 
particular attention should be paid to the development of concurrent neoplastic disease 
which is not uncommon in these age groups. There are several case reports of GCA 
developing simultaneously with malignant disease such as leukemia (252), lymphoma (253) 
and lung cancer (254). Previous suggestions of an increased risk of concomitant cancer in 
patients not responding to treatment with subsequent decline in acute phase reactants have 
not been subjected to further investigations. 
Although an increased incidence of cardiovascular disease in GCA has been suggested (255, 
256, 257, 258). these findings have not been corroborated by population surveys (21, 259). 
Thus, there exists no convincing evidence of an increased risk for development of clinically 
important cardiovascular disease in GCA, except possibly for the oldest patients with GCA 
(260). Of note, cardiovascular diseases are in general prevalent in this age group and should 
not be ignored.    
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21. Initial treatment 
After the first trial of CS therapy for the disease was reported by Schick et al in 1950 (261), 
CS have remained the mainstay of therapy in GCA. However, much is still unknown 
regarding their mechanisms of action, the optimal initial dose, speed of taper, and duration 
of CS therapy. 
22. Uncomplicated GCA 
In the absence of large vessel vasculitis, severe organ involvement or visual disturbances 
(uncomplicated GCA), low doses of CS are as effective as low doses (262, 263). Moreover, 
those patients commencing treatment with low doses of CS do not have more visual or 
neurological complications than patients treated with higher doses (264). Starting doses of 
30-40 mg of prednisolone daily are thus recommended. Both cumulative doses of CS and 
higher doses are associated with increased toxicity (265, 266, 267).    
Side effects may occur in at least one third of patients, and in two thirds if weight gain is 
included (264). Treatment with alternate-day CS administration is associated with a higher 
rate of treatment failure than is daily administration (268) and is not recommended.  
If a significant response of 30-40 mg prednisolone per day is not obtained within 6-72 hours, 
an initial dose of oral prednisolone of 60 mg should be administered. There are, however, no 
studies that clearly show that a higher dose of oral CS yields a higher response rate than 
lower doses. If response to 60 mg of prednisolone fails to occur, diagnoses other than GCA 
should be considered. Similarly, in patients whose symptoms persist without elevated acute 
phase reactants, alternative or concurrent explanations should be sought. Also those 
patients whose symptoms resolve but the acute phase reactants remain elevated should be 
subjected to further diagnostic evaluations before continuing GC treatment.     
The initial dose of CS is usually given for 2-4 weeks until all reversible signs and symptoms 
have resolved and acute phase reactants are back to normal. Then, the dose can be gradually 
reduced (269) each week or every two weeks by a maximum of 10% of the total daily dose 
with careful follow-up of systemic symptoms and acute phase reactants. 
23. Treatment of GCA presenting with visual disturbances and blindness  
Historically, experience clearly suggests a protective effect of CS against development of 
visual complications. Prior to the steroid era, a higher incidence of such ischemic events as 
compared to recent reports has been observed (17, 36, 270, 271, 272, 273). However, there are 
no randomized controlled studies proving such a preventive effect. Moreover, a substantial 
proportion of patients may loose vision in spite of daily treatment with high doses of CS 
(274, 275, 276). Finally, there is no convincing evidence to suggest that administration of GC 
results in improvement of established visual loss. Nevertheless, in patients presenting with 
visual disturbances, administration of CS should be initiated immediately, and not delayed 
until results of TAB are available. Studies have shown that if therapy is instituted within 24 
hours, the chance of visual improvement is much greater than if treatment is delayed (49). 
Usually, 60 mg of oral prednisolone per day is given (207, 208), with gradual tapering of the 
dose to 40 mg in 1-2 weeks providing a clinical response appear. Thereafter, the steroid dose 
is gradually tapered to reach a maintenance dose of 10 mg by 6-9 months, and 5-7.5 mg 
within 1 year. In one report, the median time to reach the lowest maintenance dose of 
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prednisone at which the ESR and CRP stayed low and stable was 48.7 months (277). 
However, as pointed out by Hayreh and Zimmerman (277), no generalization is possible for 
tapering down of CS, and there is no formula because of the infinite variation between 
individuals.  
Patients with loss of vision represent a challenge to the physician. Visual loss from GCA is 
typically profound and permanent (42, 278). Although still debated (47, 279), most workers 
recommend administration of 500-1000 mg methylprednisolon i.v. for three days before oral 
treatment is given (207, 208, 280, 281, 282, 283, 284). The main purpose of this treatment is to 
protect the contralateral eye (285). If the second eye is to be affected, this most often happens 
during the first 2 to 14 days (286, 287. Loss of vision after cessation of GC is very rare (36). 
Alternate day GC is not recommended (268). 
24.Treatment of patients with other extratemporal manifestations 
Treatment of patients exhibiting large vessel vasculitis involving arteries of the extremities 
or aorta in addition to temporal arteritis, patients with scalp or tongue necrosis or other 
serious extratemporal arteritis should be treated vigorously with the same 
recommendations as for those with visual impairment. For patients with large vessel 
vasculitis without involvement of the temporal arteries, a low dose regimen of CS may be 
sufficient (77). For patients developing aortic aneurysms requiering cardiac surgery, medical 
therapy should be continued at the established dose (93). 
24.1 Alternative treatment strategies 
In addition to CS-resistance, there are several other compelling reasons to search for 
alternatives to CS. High initial and cumulative doses of CS often resulting in important side 
effects, visual impairment despite adequate administration of GC, the development of aortic 
aneurysm, dilation and dissection in a significant number of patients and the frequent 
relapses and heterogeneous responses to therapy all are of major concern. Thus, alternate or 
additive therapy to reduce the CS doses, to better prevent disease complications and to 
improve therapeutic responses has been the subject of repetitive studies during the recent 
years.  
Trials of methotrexate (MTX) have yielded conflicting results (288, 289, 290). A meta-
analysis of three randomized studies (291) showed that treatment with MTX lowers the risk 
of relapse and reduces exposure to CS. The authors suggested that MTX should be 
considered as a therapeutic option in addition to standard-of-care treatment with CS for 
patients with GCA (291). However, most patients are favorably treated with CS 
monotherapy and may manage with low or modest doses. Consequently, MTX as an 
adjunctive therapy in GCA should be considered in patients requiring high doses of CS, 
particularly those having both GCA, PMR and large vessel arteritis (292). MTX may also be 
added to steroids in patients with peripheral arthritis unresponsive to local CS injections.   
Azathioprine and other traditional DMARDs have not been shown to exert any favorable 
effects in GCA (293, 294, 295), although some steroid sparing effect of azathioprine was 
found in one double-blind study (293). Similarly, statin therapy does not seem to offer any 
protection against development of visual complications, large vessel vasculitis, jaw 
claudication, ischemic heart disease, or cerebrovascular accidents (296).     
TNFǂ has been demonstrated in up to 60% of the cells in all areas of inflamed arteries (297), 
and inhibition of this cytokine may be an attractive therapeutic option in GCA. Early case 
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reports (298, 299, 300, 301, 302, 303, 304, 305) of favorable response to TNFǂ inhibitors 
indicated that biological therapy could be an alternative to CS or at least be used in patients 
failing to respond to CS. However, suggestions of efficacy of TNFǂ inhibitors have not 
withstood further drug trials. In a randomized trial, Hoffman and coworkers (306) found 
that infliximab therapy did not increase the proportion of patients without relapse at week 
22 compared with placebo nor did it increase the proportion of patients whose CS dosages 
were tapered to 10 mg/d without relapse. The results of drug trials of etanercept are, 
however, perhaps more promising (299, 300). In a study of etanercept versus placebo, 
Martinez-Taboada and coworkers showed that among GCA patients with side effects due to 
CS, etanercept treated patients more often than controls were able to control the disease 
without CS therapy (299). Clearly, the role of etanercept in CS resistant GCA awaits final 
clarification. 
Much research during the last decade has focused on the role of cytokines in GCA. Cytokines 
are small proteins that serve as chemical messengers between cells, regulating cell growth and 
differentiation, tissue repair and remodeling, and many aspects of the immune response (184). 
In GCA, the different vessel layers  produce different cytokines. Interferon-Ǆ secreting T-cells 
are almost exclusively found in the adventitial layer of the inflamed arteries (184), and appear 
to be critically involved in modulating the process of intimal hyperplasia, the most destructive 
consequence of vasculitis. Interferon-Υ thus emerges as a prime target for novel therapeutic 
approaches (184), but no randomized controlled studies have yet emerged. Interestingly, the 
histological and immunological profile in silent or masked GCA appears different from that of 
cranial arteritis. The latter is characterized by intimal hyperplasia and production of 
Interferon-Υ, IL-1ǃ and Platelet derived growth factor (PDGF) while in silent GCA there is no 
intimal hyperplasia and prominent production of IL-2 (33). Whether or not this discrepancy 
implies different therapeutic approaches and diverging outcome is yet to be shown.  
Macrophages in the adventitia produce the proinflammatory cytokines IL-1 and IL-6 (184, 185, 
186), and levels of IL-6 has been shown to be potentially helpful in predicting disease severity 
and may allow for a tailoring of immunosuppressive therapy (186). Thus, preliminary case 
reports have emerged which may indicate a beneficial effect of the anti IL-6 monoclonal 
antibody tocilizumab in both polymyalgia rheumatica and GCA (307, 308). Favorable effects of 
anti-IL-1 receptor antagonists are yet to be documented by randomized controlled trials. 
Abatacept, a recombinant fusion protein that modulates CD28-mediated T-cell costimulation is 
another tantalizing therapeutic option in GCA awaiting controlled trials.  
In a small series of patients with steroid-resistant Takayasu arteritis, another giant cell 
vasculitis, treatment with mycophenolate mofetil (MMF) resulted in clinical remission as 
well as improvement in inflammatory markers (309). However, experience with MMF in 
GCA is still lacking. Platelet derived growth factor (PDGF) appears to be a critical growth 
factor in arteries with luminal occlusion (184). Thus, the production of PDGF by 
multinucleated giant cells and macrophages may be inhibited by tyrosine kinase inhibitors, 
and preliminary in vitro observations may indicate that imatinib mesylate may have a role 
in the therapy of GCA (310). Endothelin-1 (ET-1) is one of the most powerful 
vasoconstrictors identified, and ET-1 concentrations has been found increased at the protein 
level in temporal artery samples from GCA patients (311). Moreover, plasma ET-1 
concentrations appeared higher in patient with ischemic complications (311). However, no 
study yet has been undertaken to test potential beneficial effects of antagonizing ET-1 in 
GCA. Finally, the anti-CD20 monoclonal antibody rituximab has not been subjected to 
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controlled studies, but a case report found improvement of B lymphocyte depletion in a 
patient requiring unacceptable high doses of CS (312). 
At present, no alternatives to daily CS therapy have emerged, but the role of new agents will 
hopefully be clarified in future drug trials. It is hoped that these new agents will result in 
better control of markers of inflammation which may translate into lower rates of late 
atherosclerosis and aortic aneurysms even years after the clinically active phase of the 
disease has resolved (313).  Except for a potential role in patients with visual disturbances, 
treatment with intravenous methylprednisolone does not appear to offer any long-term CS 
sparing effect. Moreover, in our experience, intramuscular methylprednisolon has no role in 
the drug treatment of GCA. 
24.2 Additive treatment 
Patients with GCA do not seem to be at increased risk of contracting  cardiovascular disease 
(314), but physicians responsible for the treatment of patients with GCA should nevertheless 
be encouraged to search for cardiovascular risk factors as they are common in this age. 
Although suggested to be of possible use in other inflammatory rheumatic diseases (315), 
there are, however, no data to support the use of statins in patients with GCA if they do not 
have cardiovascular risk factors.  
There is an ongoing discussion regarding the use of acetylsalicylic acid in patients with 
GCA. Some have suggested that treatment with low-dose aspirin may exhibit some 
protection against cranial ischemic complications (316, 317). However, more recent studies 
have been unable to detect any definite effects of aspirin in GCA (318). On the other hand, it 
cannot be excluded that the inflammatory process may have impact on the age-related long-
term risk of cardiovascular disease in these patients. In addition to its well-established 
antiplatelet effect, aspirin may also be beneficial in GCA by virtue of its inhibitory effect on 
interferon-Ǆ mRNA production, essential for the development of the inflammatory infiltrate 
of the vessel wall. Thus, low dose aspirin may prevent complications of atherosclerotic 
cardiovascular disease, not just through its antiplatelet effect, but also by its anti-
inflammatory effects during atherogenesis and by increasing plaque stability (313). Finally, 
the interferon-Ǆ production by the adventitial T lymphocytes in GCA appears relatively 
resistant to standard CS therapy, but susceptible to aspirin (313). Thus, this may further 
strengthen the indication for adding aspirin to CS in the standard therapeutic regimen of 
GCA. However, a prospective study is clearly warranted to define the role of aspirin in 
GCA. Until then, a low dose regimen of aspirin can be recommended in the absence of 
specific contraindications as an adjunctive drug in this disease. 
Steroid-related side effects are frequently recorded in GCA (264, 265, 266). Among these, the 
detrimental effects of GC is well known. Although the incidence of CS induced osteoporosis 
appears rather low in GCA (319, 320), the risk of contracting such complications should not 
be ignored. Most workers recommend addition of calcium and vitamin-D to female patients 
with GCA, at least for those patients prone to receive long-term CS therapy and requiring 
large doses. In the presence of other risk factors for osteoporosis, treatment with bisphonates 
should be considered. 
25. Follow-up and monitoring 
25.1 Maintenance therapy (dose and duration) 
High doses of oral prednisolone (40-60 mg per day) are maintained for at least 4-6 weeks 
until systemic symptoms have subsided and markers of disease activity have normalized 
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(207, 208). Then, the dose is reduced by 10 mg every 2 weeks to 20 mg. Thereafter, the dose 
is reduced by 2.5 mg every 2-4 weeks to 10 mg. Providing no relapse or development of 
extracranial complications, CS are further reduced by 1 mg every 1-2 months. In one study 
(263), mean daily maintenance dose during the first and second year was 6.6 and 4.1 mg, 
respectively. In another report, the median duration required to reach 7.5 mg/day was 6.5 
months (321).  
Patients should be monitored closely for relapse, control of disease activity, alleviation of 
complaints, development of extracranial complications and CS-induced side effects. Which 
patients that will require higher doses to control the disease are difficult to predict. It has, 
however, been suggested that a strong systemic inflammatory response is associated with 
higher CS requirements and a longer duration of therapy (217). Both ESR and CRP should 
be assessed regularly, but some data indicate that blood concentrations of interleukin 6 are 
the most sensitive indicators of disease activity and course (185, 186). However, assessment 
of IL-6 levels is not done in routine laboratories. Thus, both traditional acute phase 
parameters such as ESR and CRP and clinical evaluation of disease activity and progression 
represent the basis for deciding the therapeutic dose of CS.  
As outlined previously, one approach recommends a minimum of abdominal ultrasound, 
chest radiographs and transthoracic echocardiogram annually to search for development of 
aneurysmatic disease.  As the incidence of malignant disease in GCA is most likely similar 
to that of the general population, no recommendations can be given for screening processes 
to exclude malignancy. The age-group affected by GCA implies, however,  attention to 
coincident development of neoplasia. 
26. Cessation of treatment and relapses 
Typically, relapses are most commonly occur within the first 18 months (322), but may be 
observed as late as after 8 years of treatment (321). One or more relapses of GCA occur in 27-
62% ( 323, 324, 325, 326, 327). In patients with visual disturbances, further deterioration of 
vision usually takes place in the first 5-6 days of steroid initiation (46). Recurrences of visual 
loss most often occur between 3 and 36 months after the initial visual loss (45). Relapses are 
most commonly accompanied by increased acute phase parameters. However, both clinical 
features and acute phase reactants should be considered when diagnosing relapse, as 
neither CRP nor ESR alone can be depended on to diagnose clinical exacerbations.  A rise in 
ESR/CRP may also spark vigilance that concurrent opportunistic infection is present which 
should not be overlooked. It is recommended that the initial dose regimen is repeated if 
relapse develops. 
The total duration of GCA treatment is difficult to predict with accuracy on clinical and 
laboratory grounds. It has been suggested that the slope of prednisolon dose-tapering may 
identify at an early stage those patients who are at risk of undertaking a long period of 
treatment (328). Moreover, patients with coexisting AT and PMR appear to demand longer 
treatment (263, 329). It is still debated whether GCA patients exhibiting visual disturbances 
require longer periods of GC than those without. In one study (321), the median time to 
steroid discontinuation was 21.6 months while in another study all patients has 
discontinued GC within 24 months (329). On the other hands, our experience (263) and also 
others (330) have demonstrated that after 2 years, 80-90% of patients are still on CS. In the 
study of Hayreh and Zimmerman (277), 92.5 % of those with visual loss and 86.1 % of those 
without were still on GC five years after commencement of therapy. Clearly, the duration of 
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CS treatment is highly variable and careful monitoring of patients cessating treatment is 
strongly recommended.   
27. Concluding remarks 
There are still major delays in the recognition and treatment of GCA (65) which partly result 
in a rather high incidence of irreversible ischemic complications. Patients exibiting less 
classical clinical manifestations appear to represent a subclass in which diagnosis is 
particularly problematic. Thus, an important challenge in the care of of patients with GCA is 
to improve the skill and competence of general practioners as they are the first to meet these 
patients. Finally, research during the latest years has clearly shown the complexity of the 
immune pathology in GCA, including both Th1 and Th17 responses (331). Although GC 
remain the mainstay of therapy in GCA, cocktails of therapies will probably be needed for 
appropriate disease control (331). 
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